Certain agents, including the AhR agonist aminoflavone (AFP464) and the AhR antagonist StemRegenin-1 (SR1) (95), have been tested in clinical trials for breast neoplasms and solid tumors (NCT01015521, NCT00369200, NCT01233947) or hematological malignancies (NCT02765997), respectively. Here, AHR is linked to hematologic disorder.